Eric Singhi: MARIPOSA a path forward to help us determine who benefits from 1L combination therapy?
- TP53 co-mutation
- +ctDNA
- Liver metastases
A path forward to identify biomarkers to help us determine who benefits from 1L combination therapy? ”
Source: Eric Singhi/X
Eric Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
Dr. Singhi is highly skilled in general internal medicine and hematology/oncology, with a special focus on thoracic medical oncology. Fluent in multiple languages, including Hindi and Spanish, he is dedicated to providing personalized care and improving patient outcomes. Dr. Singhi’s interests extend to patient education, patient-reported outcomes, and community outreach.
He is affiliated with various hospitals in the Houston area, including Harris Health Ben Taub General and LBJ Hospitals, and The University of Texas MD Anderson Cancer Center. With over 6-10 years of experience, Dr. Eric Singhi is committed to delivering exceptional care to his patients and advancing the field of oncology.
